Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$14 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.9 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
1.8
Industry P/E
24.51
EV/EBITDA
0.7
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-0.9
Face value
--
Shares outstanding
13,782,372
CFO
$-106.39 Mln
EBITDA
$-300.88 Mln
Net Profit
$-303.62 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Cocrystal Pharma (COCP)
| 54.2 | 43.8 | 54.2 | 6.3 | -8.8 | -38.5 | -40.5 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Cocrystal Pharma (COCP)
| -51.5 | 17.3 | -11.8 | -75.0 | -52.2 | 174.5 | -86.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Cocrystal Pharma (COCP)
|
1.5 | 13.8 | 0.1 | -9.7 | -7,179.4 | -129.2 | -- | 1.8 |
| 12.5 | 3,981.1 | 3,018.8 | 72.1 | 12.6 | -80 | 56.7 | 86.1 | |
| 168.5 | 8,210.1 | 638.5 | -183.2 | -27.4 | -252.1 | -- | 92.9 | |
| 73.2 | 13,446.3 | 502.1 | -729.3 | -125.8 | 41.2 | -- | 123.7 | |
| 42.5 | 4,055.0 | 761.4 | 99.7 | 7.3 | 15 | 46.5 | 5.7 | |
| 13.3 | 11,120.8 | 345,831.0 | 56,586.0 | 21.5 | 15.8 | 18.2 | 2.8 | |
| 23.1 | 11,474.6 | 4,715.0 | -232.0 | 0.9 | -3.7 | -- | 1.8 | |
| 8.2 | 7,645.3 | 7,227.1 | 386.1 | 16.6 | 6.9 | 13.8 | 0.9 | |
| 199.6 | 3,841.5 | 268.1 | 124.5 | 60.0 | 13.5 | 31.5 | 4.0 | |
| 37.7 | 3,099.9 | 158.3 | -68.9 | -29.3 | -113 | -- | 69.3 |
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. It employs structure-based technologies to create antiviral... drugs including influenza virus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as norovirus, respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, a HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was founded in 2006 and is based in Bothell, Washington. Address: 19805 North Creek Parkway, Bothell, WA, United States, 98011 Read more
Co-Founder, Chairman of the Board, Chief Scientist & Chairman of Scientific Advisory Board
Dr. Roger D. Kornberg Ph.D.
Co-Founder, Chairman of the Board, Chief Scientist & Chairman of Scientific Advisory Board
Dr. Roger D. Kornberg Ph.D.
Headquarters
Bothell, WA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Cocrystal Pharma Inc (COCP) is $1.51 (NASDAQ) as of 02-Apr-2026 20:00 EDT. Cocrystal Pharma Inc (COCP) has given a return of -8.79% in the last 3 years.
Since, TTM earnings of Cocrystal Pharma Inc (COCP) is negative, P/E ratio is not available.
The P/B ratio of Cocrystal Pharma Inc (COCP) is 1.82 times as on 31-Mar-2026, a 68 discount to its peers’ median range of 5.66 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-1.17
|
2.16
|
|
2023
|
-0.97
|
0.66
|
|
2022
|
-0.41
|
0.40
|
|
2021
|
-0.33
|
0.06
|
|
2020
|
-0.68
|
0.12
|
The 52-week high and low of Cocrystal Pharma Inc (COCP) are Rs 2.67 and Rs 0.86 as of 05-Apr-2026.
Cocrystal Pharma Inc (COCP) has a market capitalisation of $ 14 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Cocrystal Pharma Inc (COCP), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.49
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.